Earnings call transcript: Medifast Q1 2026 beats EPS forecast, stock dips – Image for illustrative purposes only (Image credits: Pexels)
Baltimore – Independent coaches powering Medifast’s Optavia weight-management platform faced another quarter of contraction, as the popularity of GLP-1 medications like Ozempic eroded traditional client bases. The company posted first-quarter revenue of $76 million and a smaller-than-expected net loss, topping analyst forecasts amid a 34% sales drop year over year.[1][2] Shares in the wellness firm slid more than 2% in extended trading, reflecting investor concerns over the sustainability of its coach-led model.[3]
Coach Network Shrinks Amid Market Shifts
The number of active earning coaches plummeted 45% to 14,000 from 25,400 a year earlier, underscoring the disruptive impact of prescription weight-loss drugs on direct-selling networks.[1] These independent contractors, who earn commissions by guiding clients through Medifast’s meal-replacement programs, struggled with client acquisition as more consumers turned to medical interventions.
Revenue per coach, however, climbed 19% to $5,432, signaling improved productivity among remaining leaders. Executives highlighted this as a positive trend, with stronger field engagement and leadership advancement serving as early indicators of potential recovery.[2]
Financial Results Show Resilience
Medifast recorded a net loss of $2.1 million, or 19 cents per diluted share, far better than the consensus estimate of a 55-cent loss.[1] Revenue beat projections around $70 million, though it marked a sharp decline from the prior year’s $115.7 million.
Gross profit fell to $51.8 million, with margins contracting to 68.1% due to reduced scale on fixed costs. Selling, general, and administrative expenses dropped 36% to $55.1 million, aided by lower coach incentives, marketing spend, and a one-time gain from selling a distribution center.[1]
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $76.0M | $115.7M | -34.3%[1] |
| Net Loss | $2.1M | $0.8M | Widened[1] |
| Diluted EPS | -$0.19 | -$0.07 | Worsened[1] |
| Active Coaches | 14,000 | 25,400 | -44.9%[1] |
Pivot to Metabolic Health Strategy
Medifast continued its transformation toward broader metabolic health offerings, launching Metabolic Synchronization, a program aimed at reversing dysfunction through nutrition and coaching. CEO Dan Chard emphasized progress in this area, noting sequential improvements in coach productivity for the second straight quarter.
“We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy,” Chard said. “Backed by our differentiated science, coach-led model, and a disciplined approach to managing costs, we believe we are well positioned to drive improved performance through the remainder of 2026 and a return to sustainable, long-term growth in the years ahead.”[2]
Guidance Signals Cautious Path Forward
For the second quarter, Medifast projected revenue between $60 million and $80 million, with a per-share loss of 50 cents to $1.00. Full-year expectations held steady at $270 million to $300 million in sales and losses of $1.55 to $2.75 per share.
The firm enters this period with a robust balance sheet, including $168.9 million in cash and equivalents, zero debt, and ample working capital. Stakeholders, from coaches adapting to new realities to investors eyeing a turnaround, will watch how metabolic health initiatives counter the GLP-1 headwinds.[1]
- Monitor coach retention and productivity as key growth levers.
- Track adoption of Metabolic Synchronization among clients.
- Assess impact of cost controls on margins amid lower volume.
As Medifast’s coaches navigate a transformed wellness landscape, the company’s ability to blend science-backed programs with its proven personal coaching model will determine whether it can rebuild momentum and reward patient shareholders.